Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

NCT07376499 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Liposome Irinotecan
DRUG: Platinum
DRUG: Anlotinib
DRUG: Toripalimab

Sponsor

China Medical University, China